Clinical trial · Observational
A Retrospective Study of Immunotherapy in Conversion Therapy of Unresectable Gastric Cancer
A Retrospective Study of Sintilimab Combined With Chemotherapy in Conversion Therapy of Unresectable Locally Advanced or Stage IV Gastric Cancer/Gastroesophageal Junction Carcinoma
NCT05385809CI-TRIAL-00062099unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study was an observational, non-interventional, multicenter retrospective study to evaluate the feasibility and safety of sintilimab combined with chemotherapy (SOX or PS) in the clinical practice of unresectable locally advanced or stage IV gastric cancer/gastroesophageal junction carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Unresectable Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Surgical conversion rate
- timeFrame
- two years
Secondary outcomes (4)
- measure
- R0 resection rate
- timeFrame
- two years
- description
- Defined as no residue under the microscope after resection
- measure
- Major pathological response (MPR)
- timeFrame
- two years
- description
- MPR is defined as less than 10% residual tumor after neoadjuvant therapy
- measure
- Overall response rate ( ORR)
- timeFrame
- two years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Ages: 18-75 Years (concluding 18 and 75 Years) * Pathologically confirmed gastric/gastroesophageal junction adenocarcinoma * Unresectable, locally advanced or limited distant metastasis of IV gastric cancer(AJCC 8th) * Meets only ≤2 of the following conditions: highly locally advanced (T4b), or extensive or bulcky lymph nodes; Para-aortic lymph node metastasis(mainly 16A2/B1 region); limited liver metastasis(H1); limited Peritoneal metastasis(CY1, P1), with or without ovarian metastasis(Kukernburg tumor); * Untreated(e.g. radiotherapy, chemotherapy, target therapy, immunotherapy, et al.) * At least 1 measurable lesion by RECIST v1.1 criteria * ECOG PS: 0-2 * Received sintilimab combined with chemotherapy(SOX or PS) at least 1 cycle Exclusion Criteria: * Known Her2 positive * Patients with incomplete data or other factors affecting the judgment of efficacy and safety
References
Publications (0)
Data not yet available
No reference posted for this study.